NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization252.4 mln
Float41.42 mln
Earnings Date09/02/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
61.93
Highly suspicious
1-Year Forecast
9.40
Transformational upside
Relative Strength
20
/ 100
Significantly lagging
Debt / Equity
0.18
Very low leverage
ROE
-42.68
Deeply negative
Business Description
Adagene is a China-based biotechnology company focused on developing antibody-based treatments for cancer. Founded in 2011 and headquartered in Suzhou, the company has built a broad pipeline of drug candidates at various stages of clinical testing, targeting both solid tumors and blood cancers. Its portfolio includes several antibody therapies designed to improve how the immune system attacks cancer cells, with some already in mid-stage clinical trials and others still in early research.
